Silo Wellness Inc. a wellness company in the psychedelics and functional mushroom marketplaces, is pleased to announce that on Saturday, March 6, Silo launched its second ketamine-assisted psychedelic wellness retreat on the iconic McKenzie River in Oregon and third psychedelic retreat in 2021. “Silo Wellness is intent on helping people heal right now,” said Chief Executive Officer, Douglas K. Gordon. “We have ...

Silo Wellness Inc. ("Silo Wellness" or "the Company") (CSE: SILO), a wellness company in the psychedelics and functional mushroom marketplaces, is pleased to announce that on Saturday, March 6, Silo launched its second ketamine-assisted psychedelic wellness retreat on the iconic McKenzie River in Oregon and third psychedelic retreat in 2021.

"Silo Wellness is intent on helping people heal right now," said Chief Executive Officer, Douglas K. Gordon. "We have carefully crafted our Oregon retreat design in light of COVID-19 restrictions to permit participants to enjoy the healing power of nature in conjunction with their physician-led ketamine sessions."

This week's retreat has participants from Florida, Colorado, California, and Oregon. The retreat is designed to focus on nature and the most beautiful product of nature: the mind. During the five-day, six-night retreat, participants will explore waterfalls and experience the exhilarating, refreshing experience of whitewater rafting.The retreat agenda is focused on looking inward at the self during ketamine sessions and on teasing out personal growth through interactive group sessions. The remainder of the retreat is focused on communing with nature. There is a growing body of evidence suggesting potential mental health benefits associated with direct exposure to natural environments. There is also research and anecdotal support suggesting ketamine's potential benefit in addressing mental health issues. It is with these two bodies of research in mind that Silo Wellness has married nature to ketamine therapy in this first-of-its-kind retreat system and North America's first legal psychedelic retreat.

"In essence, our retreats facilitate and integrate the potential epiphanies and insights that are gleaned while using psychedelics," stated Mr. Gordon. "In the case of both our Oregon and Jamaica retreats, nature is a vital component of that integration."

In the United States, ketamine is a Schedule III substance under the Controlled Substance Act, meaning it has a low to moderate potential for physical and psychological dependence. Other examples of Schedule III substances include products containing less than 90 mg of codeine per dosage unit (Tylenol with codeine), anabolic steroids, and testosterone. To obtain ketamine, the prescribing physician must have an active DEA license. The use of ketamine for psychotherapy is a permitted off-label use by a prescribing physician.

All ketamine-assisted retreats of the Company are conducted by a physician that is independent of the Company. The physician qualifies and screens applicants for final acceptance, including any telephone or video consultations deemed necessary by the provider. The physician also provides consultations with each participant to screen for contraindications, appropriate diagnosis (if any), and mental preparedness for the retreat according to his own professional judgment. The physician, if the participant is deemed suitable for ketamine-assisted therapy, will prescribe ketamine to be administered under his medical supervision at the retreat location. The physician also provides pre-event information to attendees. There are individual meetings held virtually and with the group in preparation for the retreat.

Ketamine sessions and related therapy are provided solely by a physician and/or licensed counselor. Those services conducted at the retreat location are provided by the related practitioners and are not provided by or supervised by the Company. The Company does not practice medicine and is not involved with directing any medical care.

ABOUT SILO WELLNESS
The mission of Silo Wellness is to improve health and wellness by developing and introducing psychedelic medicine to reduce trauma and increase performance by destigmatizing the active compounds in psychedelics and innovating ease of administration and ingestion.   Silo Wellness intends to introduce new, safe, and affordable alternatives to current medicines by facilitating entry into new and emerging markets where psychedelics are legal by conducting ketamine and psilocybin wellness retreats and elsewhere by manufacturing and distributing functional mushrooms.

Since inception, Silo Wellness' activities have focused on: (1) development of psilocybin-free functional mushroom tinctures; (2) the development of the formulation of a psilocybin nasal spray in Jamaica; and (3) offering of Jamaican and Oregon psychedelic wellness retreats as well as the cultivation of psychedelic mushrooms in Jamaica. None of Silo Wellness' products claim to cure or mitigate any physical or mental disease, symptoms, disorders or abnormalities.

Further Information: www.silowellness.com

For further information, please contact:

Investor Relations :
David Gdanski
(604) 343-2724
IR@silowellness.com

Media Relations :
Stuart Kirby, VP of Marketing and Communications
press@silowellness.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION :

This news release contains "forward-looking information" and "forward-looking statements" (collectively, " forward-looking statements ") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: the operations and efficacy of the Company's Oregon and Jamaican retreats and the business plans of Silo Wellness. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties and the potential impact of COVID-19. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Readers should not place undue reliance on the forward-looking statements and information contained in this news release. Silo Wellness assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

Hollister Biosciences Announces Third Quarter Fiscal 2021 Financial Results Including Revenue of USD $14.5M and Adjusted Ebitda of USD $1.2M

Revenue of $14.5 million increased 53% from prior year period

Gross profit income of $3.5 million increased 151% from prior year period

Keep reading... Show less

iX Biopharma Signs Exclusive License Agreement For Wafermine And Other Sublingual Ketamine Wafer Products

  • iX Biopharma will receive an initial US$9 million upfront payment
  • Eligible for up to US$239 million in development and sales milestone payments
  • Double digit royalties on future product sales of any licensed product

IX Biopharma Ltd (SGX:42C), a specialty pharmaceutical company that develops innovative therapies using its proprietary sublingual drug delivery technology, WaferiX, announced today that it has, through its subsidiary, entered into an exclusive license agreement with Seelos Therapeutics, Inc ("Seelos") (Nasdaq: SEEL), a company focused on developing novel therapeutics for central nervous systems disorders. Under the agreement, iX Biopharma will license to Seelos its lead drug under development, Wafermine, a sublingual racemic ketamine wafer, and other products incorporating R- and S- enantiomers of ketamine utilising the WaferiX technology (the "Licensed Products").

Keep reading... Show less
Stocks2Watch's Virtual Investor Luncheon Agenda Updated for Tuesday November 30

Stocks2Watch's Virtual Investor Luncheon Agenda Updated for Tuesday November 30

Stocks2Watch Investor Series today announced their agenda is updated for the Virtual Investor Luncheon on Tuesday November 30. Individual investors, finance professionals, and analysts are invited to register now to attend the Luncheon.

REGISTER NOW AT: https://app.livestorm.co/stocks2watch/investor-luncheon-nov-30

Keep reading... Show less

What Does the FDA Think About Psychedelics?

The development of the psychedelics industry depends on myriad factors, but one of the most critical is its relationship with a principal medical authority.

The US Food and Drug Administration (FDA) is the leading authority for drug approvals in the US. This federal body determines whether medical products will ultimately reach the hands of patients.

The FDA reviews the clinical data created by established medical studies evaluating the feasibility of drug compounds or products as treatments for specific ailments.

Keep reading... Show less

Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma's Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine

- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it has entered into an exclusive license agreement (License Agreement), whereby it acquired a worldwide license (excluding China Taiwan Macau and Hong Kong ) from iX Biopharma Ltd (iX Biopharma) for Wafermine™, a sublingual racemic ketamine wafer, and a worldwide license for other sublingual ketamine wafers, delivered using a proprietary fast-dissolving wafer-based drug delivery platform technology known as WaferiX™.

Keep reading... Show less

Seelos Therapeutics Raises $20 Million in Private Placement of Senior Secured Convertible Note

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced the placement of a $22.0 million senior secured convertible note (the "Note") and shares of Seelos common stock (the "Closing Shares") to Lind Global Asset Management V, LLC, managed by The Lind Partners, a New York institutional fund manager and an existing investor in Seelos. Seelos will receive $20.0 million in gross proceeds.

Keep reading... Show less

Top News

Related News